key: cord-0887152-1q6gh5zt authors: Nagra, Deepak; Russell, Mark D; Rosmini, Stefania; Sado, Daniel; Buazon, April; Shafi, Taimur; Hamlyn, Elizabeth; Sandhu, Gurjinder; Rutherford, Andrew I; Galloway, James B title: A Kawasaki-like illness in an adult with recent SARS-CoV-2 infection date: 2021-05-18 journal: Rheumatol Adv Pract DOI: 10.1093/rap/rkab035 sha: 10c6543592208de103ca4ebc31e3404d99eb7cd9 doc_id: 887152 cord_uid: 1q6gh5zt nan Key message: Kawasaki-like illnesses are rare but important diagnoses to consider in adults with recent COVID-19. Dear Editor, Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS) is an increasingly recognised entity, with features of both Kawasaki disease and toxic shock syndrome. There have been multiple reports of this syndrome in the paediatric population (1, 2) . We describe an adult male presenting with features suggestive of Kawasaki disease following recently confirmed infection with SARS-CoV-2. A 30-year-old man of Sri Lankan ethnicity presented to our Emergency Department (ED) one month after PCR-confirmed COVID-19. His initial COVID-19 symptoms had been cough, fevers and fatigue, with resolution of these symptoms two weeks after onset. Subsequent PCR tests for SARS-CoV-2 were negative. At presentation to our ED, the patient reported 7-days of headaches, fevers, abdominal pain and vomiting. He had no other localising symptoms, including no cardiorespiratory symptoms. He was previously fit and well, and he did not take any medications. He had moved to the United Kingdom from Sri Lanka in 2015. There was no recent history of travel or known infectious contacts. At presentation, he had a heart rate of 123 bpm, respiratory rate of 22 breaths per minute, blood pressure of 90/53 mmHg, oxygen saturations of 99% on air, and temperature of 38.0°C. His GCS was 15/15. Examination revealed bilateral conjunctival injection ( Figure 1A ) and cracking of the lips ( Figure 1B ). Full systems examination was otherwise unremarkable, including no evidence of a rash or palpable lymphadenopathy. A rheumatology opinion was sought; the constellation of persistent fever, bilateral conjunctival injection, mucosal changes and myocarditis were suggestive of a Kawasaki-like illness. Intravenous immunoglobulin (IVIg) at 2 g/kg was administered over two days, in addition to oral aspirin 900 mg daily. The patient responded well, with rapid normalisation of his blood pressure, temperature and other symptoms. He was discharged home on aspirin and ramipril for cardiovascular protection, and 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 continues to do well. Four weeks after discharge from hospital, the patient noted desquamation of the palms of both hands. CT coronary angiography and repeat cardiac MRI are scheduled. In this report, we describe the successful treatment of an adult with a Kawasaki-like illness temporally In this case, the onset of symptoms one month after the initial SARS-CoV-2 infection, coupled with the negative SARS-CoV-2 PCR test on presentation to the emergency department, is strongly suggestive of an immunological-mediated process rather than direct viral insult. Recent national consensus guidelines for PIMS-TS separate the presenting phenotype into Kawasaki disease-like presentations and non-specific presentations that do not meet criteria for Kawasaki disease(4), with the recommended first-line treatment being IVIg. Adopting a similar approach for multisystem inflammatory syndrome in adults with recent COVID-19 seems pragmatic. This case highlights the ability of SARS-CoV-2 to trigger unusual immunological adverse events, and the rheumatology community need to be vigilant for these complications. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Hyperinflammatory shock in children during COVID-19 pandemic Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection -United Kingdom and United States A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process Manuscripts submitted to Rheumatology Advances in Practice